Project Details
Description
A Phase 1b/2a Double Blind, Placebo Controlled Study to Evalute the Safety, Tolerability, Pharmacodynamics, and Efficacy of CNP-103 in Participants Ages 12-35 with Recent Onsetn Stage 3 Type 1 Diabetes
| Status | Active |
|---|---|
| Effective start/end date | 3/17/25 → 3/16/36 |
Funding
- COUR PHARMACEUTICALS DEVELOPMENT CO
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.